

Mezgebe Berhe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5883086/publications.pdf>

Version: 2024-02-01

13
papers

101
citations

1937685

4
h-index

1588992

8
g-index

14
all docs

14
docs citations

14
times ranked

138
citing authors

#	ARTICLE	IF	CITATIONS
1	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
2	Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 1-3.	0.5	0
3	<i>Brucella</i> , a bacterium with multiple ways of causing infection. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 99-101.	0.5	1
4	Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. <i>Aids</i> , 2021, 35, 1957-1965.	2.2	23
5	Impact of antimicrobial selection for prophylaxis of left ventricular assist device surgical infections. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3052-3059.	0.7	3
6	The dynamic treatment of SARS-CoV-2 disease. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 572-579.	0.5	2
7	Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems. <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 187-191.	0.5	9
8	Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 30-34.	0.5	1
9	2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems. <i>Open Forum Infectious Diseases</i> , 2018, 5, S730-S731.	0.9	0
10	2143. Incidence of Infection in Patients Receiving Short vs. Long Duration of Antimicrobial Prophylaxis in Neurosurgery. <i>Open Forum Infectious Diseases</i> , 2018, 5, S631-S631.	0.9	0
11	Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin. <i>Open Forum Infectious Diseases</i> , 2017, 4, S79-S79.	0.9	1
12	Tularemia Presenting as Pulmonary Nodules in an Immunocompromised Patient. <i>Baylor University Medical Center Proceedings</i> , 2017, 30, 175-176.	0.5	4
13	Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir. <i>Baylor University Medical Center Proceedings</i> , 0, , 1-3.	0.5	1